Monkeypox (Mpox) Diagnosis Market Expansion Driven by Technological Advances: Persistence Market Research

The global monkeypox (mpox) diagnosis market has witnessed substantial growth over recent years, driven by the resurgence of outbreaks and the rising demand for accurate diagnostic tools. According to Persistence Market Research, the market was valued at approximately US$1.95 billion in 2024 and is projected to reach US$2.4 billion by 2031, registering a CAGR of 4.4% during the forecast period. The increase in cases worldwide and heightened awareness of monkeypox as a significant infectious disease have created a robust market environment for diagnostic solutions.

The leading segment in the market is molecular diagnostic tests, accounting for over 55% of the market share in 2024 due to their high accuracy and clinical reliability. Skin lesion specimens are the preferred sample type for testing, holding 63% of the total share, as lesions contain high viral loads for precise detection. Regionally, North America dominates the market, accounting for around 41% of global revenue, owing to substantial investment in healthcare R&D, advanced diagnostic infrastructure, and strong government initiatives promoting disease surveillance and testing.

Get a Sample Copy of Research Report (Use Corporate Mail id for Quick Response): https://www.persistencemarketresearch.com/samples/34755

Key Highlights from the Report

• Expansion of point-of-care testing (POCT) facilities is fueling market growth.
• Increasing awareness and surveillance drives demand globally.
• High-end technological advancements in diagnostic tools enhance revenue generation.
• Skin lesion specimens are the most utilized sample, accounting for 60% of the market share.
• Integration of monkeypox testing into broad infectious disease panels is a key growth driver.
• North America leads the market, capturing approximately 41% of global share.

Market Segmentation

The monkeypox (mpox) diagnosis market is segmented based on diagnostic test type and sample type. Molecular tests, which detect the genetic material of the virus, dominate due to their superior accuracy and reliability compared to antigen detection tests. These tests, primarily using PCR technology, provide precise results in clinical and research settings, making them a preferred choice for healthcare providers. Antigen detection tests, although faster, are less sensitive and mostly serve as complementary tools in point-of-care environments.

Segmentation based on sample type highlights skin lesion specimens as the dominant category due to the high viral concentration present in pustules, vesicles, and scabs. Other sample types include whole blood and urine, which are less frequently used because of lower viral loads. End-user segmentation identifies hospitals, diagnostic laboratories, and point-of-care testing centers as the key consumers of monkeypox diagnostic tests, with hospitals leading due to the demand for accurate, clinically validated results.

Read Detailed Analysis: https://www.persistencemarketresearch.com/market-research/monkeypox-mpox-diagnosis-market.asp

Regional Insights

North America maintains a dominant position in the monkeypox diagnosis market, driven by advanced healthcare infrastructure, substantial investment in medical research, and a high prevalence of the disease in certain areas. The U.S., in particular, has seen extensive implementation of PCR-based diagnostics and widespread adoption of point-of-care testing solutions, supporting continued market growth.

Europe follows closely, with rising awareness and government-backed initiatives promoting infectious disease testing. Countries such as Germany, the U.K., and France have integrated monkeypox testing into broader infectious disease panels, supporting early detection and containment. The Asia-Pacific region is showing promising growth due to emerging healthcare infrastructure and increased funding for infectious disease diagnostics, though market penetration is currently lower than in North America.

Market Drivers

One of the primary drivers of the monkeypox (mpox) diagnosis market is increasing global awareness and enhanced disease surveillance. The 2022 outbreak highlighted the need for early detection, prompting governments and health organizations to invest heavily in diagnostic infrastructure. Enhanced reporting systems, training programs, and public health campaigns have all contributed to the heightened demand for testing solutions.

Technological advancements in diagnostic tools also drive market expansion. The development of real-time PCR assays, next-generation sequencing, and point-of-care diagnostic kits has increased the speed, accuracy, and accessibility of testing. These innovations allow rapid detection in decentralized healthcare settings, enabling timely intervention and reducing the spread of infection.

Integration of monkeypox testing into broader infectious disease panels is another significant growth driver. Multiplex platforms allow simultaneous detection of multiple pathogens, improving clinical efficiency and reducing time to diagnosis. As hospitals and diagnostic laboratories adopt these platforms, demand for monkeypox testing rises, further stimulating market growth.

Market Restraints

Despite the growth potential, limited awareness and insufficient testing infrastructure in developing regions restrict market expansion. Many countries lack the necessary laboratories, trained personnel, and resources for widespread diagnostic implementation. Public health funding constraints and competing healthcare priorities can further slow adoption.

Regulatory challenges also impede growth. The diagnostic market is subject to stringent and varied regulations across countries, making it time-consuming and costly for companies to obtain approvals for new tests. Compliance with international standards can be particularly challenging for smaller firms, delaying product launches and hindering market penetration in certain regions.

Market Opportunities

Expansion of point-of-care testing (POCT) represents a significant opportunity for the monkeypox diagnosis market. Portable, rapid diagnostic kits enable immediate testing in remote or resource-limited areas, facilitating faster detection and containment. This decentralization reduces reliance on centralized laboratories, improving outbreak management and overall healthcare responsiveness.

Emerging markets offer further opportunities as healthcare infrastructure continues to develop. Incorporating monkeypox testing into routine diagnostic panels can expand market reach and promote early detection. Investments in multiplex assays, next-generation sequencing, and rapid antigen detection are likely to open new revenue streams for market players.

Advancements in artificial intelligence and data analytics for diagnostic interpretation provide another growth avenue. AI-powered platforms can enhance result accuracy, reduce human error, and optimize testing workflows, offering significant advantages in clinical settings.

Request for Customization of the Research Report: https://www.persistencemarketresearch.com/request-customization/34755

Reasons to Buy the Report

• Gain comprehensive insights into market size, growth trends, and projections.
Identify key growth drivers, restraints, and opportunities shaping the market.
• Analyze market segmentation by diagnostic test, sample type, and end-user.
Understand regional dynamics and competitive landscapes for strategic planning.
• Access detailed profiles of key players and recent market developments.

Frequently Asked Questions (FAQs)

• How big is the monkeypox (mpox) diagnosis market globally?
• Who are the key players in the global market for monkeypox (mpox) diagnosis?
• What is the projected growth rate of the monkeypox (mpox) diagnosis market?
• What is the market forecast for monkeypox (mpox) diagnosis in 2032?
• Which region is estimated to dominate the industry through the forecast period?

Company Insights

The monkeypox (mpox) diagnosis market is highly competitive, with several key players leading the landscape:

• Roche
• Abbott Laboratories
• Cepheid
• Thermo Fisher Scientific
• Becton, Dickinson and Company
• Quest Diagnostics
• Bio-Rad Laboratories, Inc.
• bioMérieux SA
• CerTest Biotec
• Laboratory Corporation of America Holdings

Recent Developments

• September 2022 - Quest Diagnostics received emergency use authorization (EUA) from the FDA for its molecular diagnostic test for monkeypox.
• June 2022 - CerTest Biotec partnered with Becton, Dickinson and Company to develop a molecular test for the detection of the monkeypox virus.

Conclusion

The monkeypox (mpox) diagnosis market is poised for steady growth driven by increasing global awareness, technological advancements, and the integration of testing into comprehensive infectious disease panels. North America currently leads due to substantial healthcare investments and advanced diagnostic infrastructure, while emerging regions show promising potential. With point-of-care testing, multiplex diagnostics, and AI-enabled solutions shaping the future, the market presents lucrative opportunities for both established players and new entrants. Strategic investments, regulatory compliance, and innovation will be pivotal in sustaining market momentum and meeting the global need for reliable monkeypox diagnostics.

Read More Related Reports:

Microcentrifuge Spin Column Kits Market https://www.persistencemarketresearch.com/market-research/microcentrifuge-spin-column-kits-market.asp
Middle Ear Infections Treatment Market https://www.persistencemarketresearch.com/market-research/middle-ear-infections-treatment-market.asp
Intravitreal Ivt Injectable Market https://www.persistencemarketresearch.com/market-research/intravitreal-ivt-injectable-market.asp
Oral Hygiene Products Market https://www.persistencemarketresearch.com/market-research/oral-hygiene-products-market.asp
Norovirus Infection Diagnostics Market https://www.persistencemarketresearch.com/market-research/norovirus-infection-diagnostics-market.asp

Contact Us:

Persistence Market Research
G04 Golden Mile House, Clayponds Lane
Brentford, London, TW8 0GU UK
USA Phone: +1 646-878-6329
UK Phone: +44 203-837-5656
Email: sales@persistencemarketresearch.com
Web: https://www.persistencemarketresearch.com

About Persistence Market Research:

At Persistence Market Research, we specialize in creating research studies that serve as strategic tools for driving business growth. Established as a proprietary firm in 2012, we have evolved into a registered company in England and Wales in 2023 under the name Persistence Research & Consultancy Services Ltd. With a solid foundation, we have completed over 3600 custom and syndicate market research projects, and delivered more than 2700 projects for other leading market research companies' clients.

Our approach combines traditional market research methods with modern tools to offer comprehensive research solutions. With a decade of experience, we pride ourselves on deriving actionable insights from data to help businesses stay ahead of the competition. Our client base spans multinational corporations, leading consulting firms, investment funds, and government departments. A significant portion of our sales comes from repeat clients, a testament to the value and trust we've built over the years.

This release was published on openPR.